Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Virulence ; 11(1): 170-182, 2020 12.
Article in English | MEDLINE | ID: mdl-32052695

ABSTRACT

The comparison of the host immune response when challenged with pathogenic and nonpathogenic species of mycobacteria can provide answers to the unresolved question of how pathogens subvert or inhibit an effective response. We infected human monocyte derived macrophages (hMDMs) with different species of mycobacteria, in increasing order of pathogenicity, i.e. M. smegmatis, M. bovis BCG, and M. tuberculosis R179 that had been cultured in the absence of detergents. RNA was isolated post-infection and transcriptomic analysis using amplicons (Ampliseq) revealed 274 differentially expressed genes (DEGs) across three species, out of which we selected 19 DEGs for further validation. We used qRT-PCR to confirm the differential expression of 19 DEGs. We studied biological network through Ingenuity Pathway Analysis® (IPA) which revealed up-regulated pathways of the interferon and interleukin family related to the killing of M. smegmatis. Apart from interferon and interleukin family, we found one up-regulated (EIF2AK2) and two down-regulated (MT1A and TRIB3) genes as unique potential targets found by Ampliseq and qRT-PCR which may be involved in the intracellular mycobacterial killing. The roles of these genes have not previously been described in tuberculosis. Multiplex ELISA of culture supernatants showed increased host immune response toward M. smegmatis as compared to M. bovis BCG and M.tb R179. These results enhance our understanding of host immune response against M.tb infection.


Subject(s)
Immunity/immunology , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/metabolism , Transcriptome , Tuberculosis/immunology , Cytokines/genetics , Cytokines/metabolism , Gene Expression Profiling , Humans , Macrophages/immunology , Mycobacterium bovis , Mycobacterium smegmatis , Tuberculosis/genetics , Tuberculosis/microbiology
2.
Tuberculosis (Edinb) ; 111: 78-85, 2018 07.
Article in English | MEDLINE | ID: mdl-30029919

ABSTRACT

The emerging resistance of tuberculosis (TB) to current first line drugs (isoniazid, rifampicin, pyrazinamide, ethambutol) warrants alternative treatment approaches with broad-spectrum efficacy. Previously, we have shown that sulfamethoxazole (SMX) has synergestic activity with rifampicin against Mycobacterium tuberculosis. The primary target of SMX is folP1 in mycobacteria; however, SMX may affect other secondary targets in M. tuberculosis. This study investigated the potential additional targets of SMX in a clinical isolate of M. tuberculosis using Orbitrap mass spectrometry to identify differentially expressed proteins following treatment with a sub-lethal concentration of SMX. Raw data have been deposited as ProteomeXchange accession PXD009315. Our proteomic analysis identified approximately 1500 proteins in total of which 45 proteins were differentially regulated as a result of SMX treatment. These included 25 upregulated and 20 downregulated proteins. The oxidative stress proteins (Rv2428, AhpC and Rv2394, GgtB) and an enzyme from the electron transport chain (Ndh-II, Rv1854c) were found to be upregulated. Gene expression analysis correlated with the observed proteomic changes. In conclusion our results show that SMX treatment of a drug sensitive M. tuberculosis clinical isolate resulted in the regulation of proteins involved in the oxidative stress response, indicating the induction of oxidative stress by SMX in mycobacteria.


Subject(s)
Antitubercular Agents/pharmacology , Bacterial Proteins/metabolism , Mycobacterium tuberculosis/drug effects , Oxidative Stress/drug effects , Proteomics/methods , Sulfamethoxazole/pharmacology , Bacterial Proteins/genetics , Chromatography, Reverse-Phase , Gene Expression Regulation, Bacterial/drug effects , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/metabolism , Tandem Mass Spectrometry
3.
PLoS One ; 12(10): e0185068, 2017.
Article in English | MEDLINE | ID: mdl-28972974

ABSTRACT

Glutamine synthetase is a ubiquitous central enzyme in nitrogen metabolism that is controlled by up to four regulatory mechanisms, including adenylylation of some or all of the twelve subunits by adenylyl transferase. It is considered a potential therapeutic target for the treatment of tuberculosis, being essential for the growth of Mycobacterium tuberculosis, and is found extracellularly only in the pathogenic Mycobacterium strains. Human glutamine synthetase is not regulated by the adenylylation mechanism, so the adenylylated form of bacterial glutamine synthetase is of particular interest. Previously published reports show that, when M. tuberculosis glutamine synthetase is expressed in Escherichia coli, the E. coli adenylyl transferase does not optimally adenylylate the M. tuberculosis glutamine synthetase. Here, we demonstrate the production of soluble adenylylated M. tuberulosis glutamine synthetase in E. coli by the co-expression of M. tuberculosis glutamine synthetase and M. tuberculosis adenylyl transferase. The differential inhibition of adenylylated M. tuberulosis glutamine synthetase and deadenylylated M. tuberulosis glutamine synthetase by ATP based scaffold inhibitors are reported. Compounds selected on the basis of their enzyme inhibition were also shown to inhibit M. tuberculosis in the BACTEC 460TB™ assay as well as the intracellular inhibition of M. tuberculosis in a mouse bone-marrow derived macrophage assay.


Subject(s)
Adenosine Monophosphate/metabolism , Drug Discovery , Glutamate-Ammonia Ligase/antagonists & inhibitors , Mycobacterium tuberculosis/enzymology , Animals , Antitubercular Agents/pharmacology , Dose-Response Relationship, Drug , Glutamate-Ammonia Ligase/metabolism , HeLa Cells , Humans , Mice , Microbial Sensitivity Tests , Mycobacterium tuberculosis/drug effects
4.
Tuberculosis (Edinb) ; 100: 53-60, 2016 09.
Article in English | MEDLINE | ID: mdl-27553410

ABSTRACT

The culturing of mycobacteria is a standard procedure that is consistent world-wide, with little variation in the growth media constituents, particularly those found in liquid and solid media. Before the 1940s however, the aggregating nature of mycobacteria as well as the characteristic slow growth-rate saw mycobacterial research delay considerably. Dubos and colleagues addressed both these issues and observed that a very small volume of Tween detergent was sufficient to greatly improve the culturing of mycobacteria. Over the years however, evidence of the unfavourable effects of this detergent on a number of morphological, biochemical, pathogenic and host-interacting properties of mycobacteria surfaced. For the first time we bring together literature, past and present to comprehensively review the mycobacterial properties which are, and are not affected by the use of this detergent. We also address other detergents and methods which may circumvent the need to include Tween compounds in mycobacterial culture media.


Subject(s)
Mycobacterium/pathogenicity , Bacteriological Techniques/methods , Cell Wall/drug effects , Culture Media , Detergents/pharmacology , Host-Pathogen Interactions/drug effects , Humans , Microbial Sensitivity Tests/methods , Mycobacterium/drug effects , Mycobacterium/growth & development , Virulence/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...